Analysts Set Expectations for Biohaven FY2025 Earnings

Key Points

• Analysts at Cantor Fitzgerald have reduced their FY2025 earnings per share (EPS) estimate for Biohaven to ($7.54), down from a previous estimate of ($6.80), while maintaining a "Strong-Buy" rating.
• Multiple analysts have lowered their target prices for Biohaven, with Bank of America dropping theirs from $50 to $49, and HC Wainwright reducing it from $54 to $30, while maintaining a "buy" rating.
• Biohaven's stock has a consensus rating of "Buy" with an average price target of $53.75, despite current trading at $14.24 after a decline of 1.0% on Thursday.

Biohaven Ltd. (NYSE:BHVN - Free Report) - Investment analysts at Cantor Fitzgerald lowered their FY2025 EPS estimates for shares of Biohaven in a research note issued on Tuesday, August 12th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will earn ($7.54) per share for the year, down from their previous forecast of ($6.80). Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for Biohaven's current full-year earnings is ($8.90) per share. Cantor Fitzgerald also issued estimates for Biohaven's FY2026 earnings at ($5.92) EPS.

Other research analysts also recently issued reports about the stock. Bank of America dropped their target price on shares of Biohaven from $50.00 to $49.00 and set a "buy" rating on the stock in a research report on Tuesday. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price (down from $54.00) on shares of Biohaven in a research report on Tuesday. Morgan Stanley dropped their target price on shares of Biohaven from $63.00 to $54.00 and set an "overweight" rating on the stock in a research report on Tuesday. Robert W. Baird dropped their target price on shares of Biohaven from $57.00 to $52.00 and set an "outperform" rating on the stock in a research report on Tuesday. Finally, JPMorgan Chase & Co. dropped their target price on shares of Biohaven from $68.00 to $55.00 and set an "overweight" rating on the stock in a research report on Wednesday, June 18th. One analyst has rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Biohaven has a consensus rating of "Buy" and an average price target of $53.75.

Biohaven Stock Down 1.0%

Biohaven stock traded down $0.15 during mid-day trading on Thursday, reaching $14.24. 37,688 shares of the company's stock were exchanged, compared to its average volume of 1,673,526. The company has a market cap of $1.51 billion, a P/E ratio of -1.85 and a beta of 0.98. Biohaven has a twelve month low of $12.79 and a twelve month high of $55.70. The company has a quick ratio of 2.33, a current ratio of 3.82 and a debt-to-equity ratio of 1.91. The company has a fifty day moving average of $14.56 and a 200-day moving average of $22.27.

Biohaven (NYSE:BHVN - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($1.94) EPS for the quarter, hitting the consensus estimate of ($1.94).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Ameriprise Financial Inc. raised its holdings in Biohaven by 40.0% in the fourth quarter. Ameriprise Financial Inc. now owns 508,682 shares of the company's stock valued at $18,994,000 after acquiring an additional 145,331 shares in the last quarter. LPL Financial LLC raised its holdings in Biohaven by 4.1% in the fourth quarter. LPL Financial LLC now owns 42,190 shares of the company's stock valued at $1,576,000 after acquiring an additional 1,664 shares in the last quarter. KBC Group NV raised its holdings in Biohaven by 35.0% in the first quarter. KBC Group NV now owns 4,560 shares of the company's stock valued at $110,000 after acquiring an additional 1,183 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Biohaven in the fourth quarter valued at $1,384,000. Finally, Parallel Advisors LLC raised its holdings in Biohaven by 319.8% in the first quarter. Parallel Advisors LLC now owns 1,360 shares of the company's stock valued at $33,000 after acquiring an additional 1,036 shares in the last quarter. 88.78% of the stock is currently owned by hedge funds and other institutional investors.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.